Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab
- PMID: 16137435
- DOI: 10.3816/CBC.2005.n.026
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab
Abstract
Background: We evaluated the influence of HER2 gene amplification, as determined by fluorescence in situ hybridization (FISH), on clinical outcomes (objective response rates, time to disease progression, and overall survival time) in women with metastatic breast cancer treated with trastuzumab in 3 clinical trials. Breast cancer tissue specimens were evaluated using a direct labeled, dual-probe FISH assay.
Materials and methods: Specimens with a HER2:CEP17 ratio of > or = 2:0 were considered positive for gene amplification. All specimens had previously demonstrated overexpression of HER2 protein at the 2+ or 3+ level by immunohistochemistry using the Clinical Trials Assay. Response rate, time to disease progression, and survival times were then compared between the FISH-positive and FISH-negative cohorts in each of the 3 clinical trials.
Results: Informative FISH results were obtained in 765 (96%) of the 799 patients enrolled in the 3 clinical trials. Overall, 596 (78%) were FISH-positive and 169 (22%) were FISH-negative. The proportion of FISH-positive patients was comparable in all 3 trials. Clinical benefit from trastuzumab therapy appeared to be restricted to patients with FISH-positive metastatic breast cancer. In each clinical trial, the cohort of FISH-positive patients had higher overall response rates and longer durations of survival compared with FISH-negative patients.
Conclusion: These data indicate that assessment of HER2 amplification by FISH is the preferred method to select patients for trastuzumab therapy.
Similar articles
-
Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.Breast Cancer Res Treat. 2005 Sep;93(1):3-11. doi: 10.1007/s10549-004-6275-8. Breast Cancer Res Treat. 2005. PMID: 16184453
-
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.Cancer. 2010 Nov 15;116(22):5168-78. doi: 10.1002/cncr.25430. Cancer. 2010. PMID: 20661914
-
Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.Clin Breast Cancer. 2005 Aug;6(3):247-52. doi: 10.3816/CBC.2005.n.027. Clin Breast Cancer. 2005. PMID: 16137436
-
Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.Oncol Nurs Forum. 2006 Nov 3;33(2):265-72. doi: 10.1188/06.ONF.265-272. Oncol Nurs Forum. 2006. PMID: 16518442 Review.
-
[Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].Orv Hetil. 2001 Nov 18;142(46):2563-8. Orv Hetil. 2001. PMID: 11770175 Review. Hungarian.
Cited by
-
Patient characteristics and treatment patterns of patients with locally advanced or metastatic HER2-low breast cancer, a single site descriptive study.Breast Cancer Res Treat. 2024 Aug 22. doi: 10.1007/s10549-024-07458-9. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39172305
-
Label-free electrochemical cancer cell detection leveraging hemoglobin-encapsulated silver nanoclusters and Cu-MOF nanohybrids on a graphene-assisted dual-modal probe.Sci Rep. 2023 Dec 11;13(1):21980. doi: 10.1038/s41598-023-49418-1. Sci Rep. 2023. PMID: 38082024 Free PMC article.
-
Novel RICTOR amplification harbouring entities: FISH validation of RICTOR amplification in tumour tissue after next-generation sequencing.Sci Rep. 2023 Nov 10;13(1):19610. doi: 10.1038/s41598-023-46927-x. Sci Rep. 2023. PMID: 37949943 Free PMC article.
-
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level.Br J Cancer. 2023 Nov;129(10):1692-1705. doi: 10.1038/s41416-023-02426-4. Epub 2023 Sep 22. Br J Cancer. 2023. PMID: 37740038 Free PMC article.
-
History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer.J Clin Med. 2023 May 10;12(10):3391. doi: 10.3390/jcm12103391. J Clin Med. 2023. PMID: 37240498 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous